Electrocore yesterday registered for an initial public offering worth nearly $75 million, detailing plans to expand its GammaCore device beyond the two headache treatments it’s already cleared for in the U.S.
The Basking Ridge, N.J.-based company said in a regulatory filing that it plans to use the $74.8 million IPO’s net proceeds to expand its sales territories ahead of a full U.S. launch for GammaCore; R&D into other headache and rheumatology indications; and a specialty distribution channel for the GammaCore Sapphire device. The company would trade on the NASDAQ exchange under the “ECOR” symbol, according to the filing.
The cash could also go toward M&A, but no plans are in place for any transactions, Electrocore said. The initial IPO registration was filed confidentially Feb. 13, with the company reporting sales of $1 million for the 12 months ended March 31. ElectroCore filed confidentially on February 13, 2018. founded in 2005 and booked $1 million in sales for the 12 months ended March 31, according to the SEC filing unveiled yesterday.
The GammaCore device is a non-invasive, hand-held vagus nerve stimulation device designed for the reduction of pain that delivers electrical stimulation through the skin to activate the vagus nerve. Its successor, the Sapphire iteration, is a rechargeable and reloadable version intended for multi-year use, the Electrocore said.
The company, which won 510(k) clearance from the FDA for an expanded adult migraine indication for GammaCore in January, banked a $70 million Series B round last year. The device first won FDA approval for adult cluster headache in April 2017 and was launched later that summer.
Piper Jaffray and Evercore ISI are joint book-runners for the flotation, according to the filing.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.